home / stock / stml / stml news

STML News and Press, Stemline Therapeutics Inc. From 05/10/19

Stock Information
Company Name: Stemline Therapeutics Inc.
Stock Symbol: STML
Market: NASDAQ
Website: stemline.com
Menu
STML STML Quote STML Short STML News STML Articles STML Message Board
Get STML Alerts

News, Short Squeeze, Breakout and More Instantly...
STML - Stemline Therapeutics Reports First Quarter 2019 Financial Results

Net revenue for ELZONRIS was $5.05 million for the first quarter Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the de...
STML - Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019

NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will host a conference call and live webcast ...

STML - Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results

NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the pivotal trial results of ELZONRIS™ (tagraxof...

STML - Stemline Therapeutics Has The 'Big Mo'

Investing in a startup does not make you an entrepreneur any more than buying a grand piano makes you a concert pianist .” ― Jeffrey Fry Today we revisit Stemline Therapeutics ( STML ), a member of the 20-stock Busted IPO Forum model portfolio. The stock jumped over 15...
STML - Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference

NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’s CEO, was select...

STML - Stemline Therapeutics, Inc. misses by $0.18

Stemline Therapeutics, Inc. (NASDAQ: STML ): Q4 GAAP EPS of -$0.92 misses by $0.18. More news on: Stemline Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

STML - Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline

NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that it has exclusively licensed worldwide rights to develop...
STML - Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference

NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will prese...

STML - Key events next week - healthcare

Noteworthy events during the week of February 17 - 23 for healthcare investors. More news on: Allakos, Stemline Therapeutics, Aimmune Therapeutics, Healthcare stocks news, , Read more ...

STML - Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)

NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the European Medicines Agency (EMA) has completed its va...
Previous 10 Next 10